Abstracts tagged "rheumatoid arthritis (RA) and spondylarthritis"

Abstract Number: 2117 • 2019 ACR/ARP Annual Meeting
Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis
DOROTHEE VINSON¹, LUC MOLLET-BENHAMOU ², Yannick Degboe ³, Thao Pham ⁴, Thomas BARNETCHE ⁵, Arnaud Constantin ⁶ and Adeline Ruyssen-Witrand ⁷, ¹AP-HM CHU Marseille, Marseille, France, ²CHU Toulouse, Toulouse, France, ³University of Glasgow, Glasgow, United Kingdom, ⁴Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ⁵CHU Bordeaux, Toulouse, France, ⁶CHU TOUOUSE, TOULOUSE, France, ⁷Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France
Background/Purpose: A previous meta-analysis1 showed that tapering of bDMARDs does not increase the risk of relapse in rheumatoid arthritis (RA) patients with remission or low…
Abstract Number: 517 • 2018 ACR/ARHP Annual Meeting
Effects of Statin-Treatment on Coronary Plaques in Patients with Inflammatory Joint Diseases
Silvia Rollefstad¹, Mona Svanteson², Nils Einar Kløw^2,3, Jonny Hisdal⁴, Eirik Ikdahl⁵, Joseph Sexton⁶, Ylva Haig² and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Division of Radiology and Nuclear Medicine, Oslo University Hospital, Ullevål, Oslo, Norway, ³Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, ⁴Department of Vascular investigations, Oslo University Hospital, Aker, Oslo, Norway, ⁵Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Effects of Statin-treatment on Coronary Plaques in Patients with Inflammatory Joint DiseasesBackground/Purpose: Statins have an established preventive effect on coronary artery disease in the general…
Abstract Number: 698 • 2018 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Michael D. George¹, Joshua Baker² and Alexis Ogdie³, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ³Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Methotrexate and TNF inhibitors (TNFi) are commonly used in the treatment of RA, PsA, and other SpA. While MTX is a mainstay of RA…
Abstract Number: 2502 • 2018 ACR/ARHP Annual Meeting
Influence of the Treatment with Biologic Agents in the Viremia By the Endogenous Anelovirus Torque Teno Virus in Patients with Chronic Arthritis
Maria Martin-Lopez¹, Eliseo Albert², Esther Rodriguez-Almaraz³, Isidoro Gonzalez-Alvaro⁴, Mario Fernandez-Ruiz⁵, Jose M. Aguado⁵, David Navarro² and Jose L. Pablos⁶, ¹Rheumatology Department, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, ²Microbiology, Instituto de Investigación INCLIVA, Hospital Clínico, Valencia, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Instituto de Investigación Hospital 12 de Octubre. Unit of Infectious Diseases, Madrid, Spain, ⁶Rheumatology, Rheumatology Department, Hospital Universitario 12 de Octubre, Spain, Madrid, Spain
Background/Purpose: Torque teno virus (TTV) is an endogenous anellovirus that is highly prevalent in adult healthy subjects (up to 90%) without known pathogenicity. Increased replication…
Abstract Number: 463 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol for Fatigue in Chronic Inflammatory Rheumatic Diseases: A Meta-Analysis
Yesim Ozguler¹, Sinem Nihal Esatoglu¹, Guzin Karatemiz¹, Ali Ugur Unal², Gul Guzelant¹, Elif Dincses³, Mustafa Erdogan¹, Sema Kaymaz Tahra² and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Departement of Internal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey
Background/Purpose: Fatigue is an important problem that impairs life quality in patients with rheumatic diseases. Although fatigue is often associated with disease activity, only a…
Abstract Number: 2800 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial
Guro Løvik Goll¹, Kristin Kaasen Jørgensen², Joe Sexton¹, Inge C Olsen³, Nils Bolstad⁴, Merete Lorentzen⁵, Espen A. Haavardsholm⁶, Cato Mork⁷, Jorgen Jahnsen⁸ and Tore K Kvien⁹, ¹Dept Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept of cancer and Molecular medicine, Norwegian University of Science and Technology, Trondheim, Norway, ⁸Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁹Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) , Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
Abstract Number: 2169 • 2016 ACR/ARHP Annual Meeting
Presence of Cardiovascular Risk Factors Across Different Inflammatory Joint Disease Entities: Results from a Norwegian, Multi-Centre Project
Grunde Wibetoe¹, Eirik Ikdahl², Silvia Rollefstad², Anne Salberg³, Dag Magnar Soldal⁴, Tore K Kvien⁵, Glenn Haugeberg⁶ and Anne Grete Semb⁷, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Diakonhjemmet Hospital, Oslo, Norway, ³Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Martina Hansens Hospital, Bærum, Norway, ⁷Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: EULAR recommendations for cardiovascular disease (CVD) risk management in inflammatory joint diseases (IJD) advocates annual CVD risk assessments to reduce the increased CVD risk.…
Abstract Number: 2930 • 2016 ACR/ARHP Annual Meeting
Specific Metabolic and Functional Changes in Peripheral CD8+ T Cells Specifically Distinguish RA from PSA and SPA
Rui Carvalho¹, Christine Tucher², Lars Tykocinski², Susanne Neu², Karel Klika³, H.-M. Lorenz² and Margarida Souto-Carneiro², ¹Life Sciences Department, FCTUC, Center for Functional Ecology, University of Coimbra, Coimbra, Portugal, ²Rheumatology, Department of Rheumatology, University of Heidelberg, Heidelberg, Germany, ³German Cancer Research Center, Heidelberg, Germany
Background/Purpose: Studies by our team and others have shown that CD8 T cells (CD8s) in RA have a pro-inflammatory, cytotoxic effector phenotype and may, therefore,…
Abstract Number: 1169 • 2016 ACR/ARHP Annual Meeting
A Systematic Review of Rheumatic Disease Epidemiology in the Indigenous Populations of Canada, the United States, Australia and New Zealand
Cairistin McDougall¹, Kelle Hurd¹ and Cheryl Barnabe², ¹University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Two important reviews have summarized the epidemiology of rheumatic disease (Peschken 1999) and RA (Ferucci 2005) in Indigenous populations of North America. Our objective…
Abstract Number: 675 • 2015 ACR/ARHP Annual Meeting
Vitamin D Deficiency in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. Results of the CARMA Study
Ana Urruticoechea¹, Maria Auxiliadora Martin², Santos Castañeda³, Carlos Alberto Sánchez-Piedra², Carlos González-Juanatey⁴, Javier Llorca⁵, Federico Díaz-González⁶ and Miguel Angel Gonzalez-Gay⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Investigation Unit, Sociedad Española de Reumatológía, Madrid, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: To study the association between 25-hydroxyvitamin D (25(OH)D) levels and the clinical characteristics of patients with chronic inflammatory rheumatic diseases (CIRD). Methods: Cross section…
Abstract Number: 1537 • 2015 ACR/ARHP Annual Meeting
Effect of TNF-Alpha Blockade on Body Composition in Inflammatory Rheumatic Disease: Systematic Review with Meta-Analysis
sarah marouen¹, Thomas Barnetche², Bernard Combe³, Jacques Morel⁴ and Claire I. Daien⁴, ¹Rhumatology Department, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: Patients with chronic inflammatory rheumatic disease have elevated circulating concentrations of TNF-alpha and other pro-inflammatory cytokines that can modify body composition. Metabolic changes are…
Abstract Number: 2824 • 2015 ACR/ARHP Annual Meeting
Autoantibodies Against CD74 – a New Diagnostic Marker for Spondyloarthritis (SpA)
Bruno Larida, AESKU.DIAGNOSTICS INC, Oakland, CA
Background/Purpose: Spondyloarthritis (SpA) is a common debilitating inflammatory disorder. The pathogenesis of axial spondyloarthritis (axSpA) including ankylosing spondylitis (AS), although known to be strongly associated…
Abstract Number: 2874 • 2015 ACR/ARHP Annual Meeting
Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings
Leonardo Santo¹, Angelo Semeraro², Carmelo Zuccaro³, Maria Grazia Anelli⁴, Romano Bucci⁵, Antonio Marsico⁶, Laura Quarta⁷, Giorgio Carlino⁸, Francesco Paolo Cantatore⁹, Annamaria Gaudio¹⁰, Fabio Cacciapaglia¹¹, Oriana Casilli¹², Paola Chiara Francesca Falappone¹³ and Florenzo Iannone¹⁴, ¹DSS4 Barletta, ASL BT Andria - Rheumatology Service, Barletta, Italy, ²Unità Operativa di Reumatologia ASL Taranto, Taranto, Italy, ³U.O.of Geriatrics, Outpatient clinic of Rheumatology, Brindisi, Italy, ⁴DIM, Rheumatology Unit, Bari, Italy, ⁵A.O.U., Rheumatology Hospital Unit, Foggia, Italy, ⁶Outpatient clinic of Rheumatology, Taranto,, Italy, ⁷Department of Rheumatology, "V.Fazzi" Hospital, San Cesario di Lecce, Italy, ⁸ASL LE - DSS Casarano and Gallipoli, Rheumatology Service, Gallipoli, Italy, ⁹Department of Rheumatology, University of Foggia,, Foggia, Italy, ¹⁰Department of Rheumatology, University of Foggia, Foggia, Italy, ¹¹Internal Medicine Unit and Outpatient clinic of Rheumatology, “N. Melli” Hospital, San Pietro Vernotico (BR), Italy, ¹²Department of Rheumatology, "Vito Fazzi" Hospital, San Cesario di Lecce, Italy, ¹³Internal Medicine Unit - Outpatient clinic of Rheumatology,, "S. Camillo de' Lellis" Hospital, Mesagne (BR), Italy, ¹⁴Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy
Background/Purpose: It has previously been shown that the survival of anti-TNF drugs was lower in Rheumatoid arthritis (RA) than in other chronic arthritis1. The objective…
Abstract Number: 2208 • 2014 ACR/ARHP Annual Meeting
Ovarian Reserve Alterations in Premenopausal Women with Rheumatoid Arthritis, Behcet’s Disease and Spondyloarthritis – Impact on Anti-Muellerian Hormone Levels
Joerg C. Henes¹, Julia Froeschlin², Andre Taran³, Theodoros Xenitidis⁴ and Melanie Henes⁵, ¹Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ²University Tuebingen, Tuebingen, Germany, ³University Hospital for Women Tuebingen, Tuebingen, Germany, ⁴Internal Medincine II, devision for Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁵University Hospital for Women, Tuebingen, Germany
Background/Purpose: Recent publications showed a negative influence of systemic lupus erythematosus and antiphospholipid antibody syndrome on female ovarian reserve (OR). Other authors did not find…
Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)
Saedis Saevarsdottir¹, Michele Santacatterina², Carl Turesson³, Helena Forsblad⁴, Lennart Jacobsson⁴ and Staffan Lindblad⁵, ¹Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].